Analytical Data
-
基因名
SLC22A9
- Application
-
别名
SLC22A9; hOAT4; OAT7; UST3; Solute carrier family 22 member 9; Organic anion transporter 7
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8IVM8
-
表达区间
1-238 aa
-
氨基酸序列
MAFQDLLGHAGDLWRFQILQTVFLSIFAVATYLHFMLENFTAFIPGHRCWVHILDNDTVSDNDTGALSQDALLRISIPLDSNMRPEKCRRFVHPQWQLLHLNGTFPNTSDADMEPCVDGWVYDRISFSSTIVTEWDLVCDSQSLTSVAKFVFMAGMMVGGILGGHLSDSSRVGNTQIPGHGNYIGNVPFWYCIYDPGRPGFCHSRLAYPPAGGVCTILCDLSDLKLAARVCSVAHYQQ
-
分子量
52.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC22A9, a member of the solute carrier family 22, is a gene that encodes a protein involved in the transport of organic cations, including various drugs and metabolites, across cellular membranes. Its function has garnered significant attention due to its potential implications in pharmacokinetics and the therapeutic efficacy of numerous medications. Dysregulation of SLC22A9 expression has been associated with various diseases, including cancer and metabolic disorders, suggesting its role in drug resistance and personalized medicine. Research on the recombinant SLC22A9 protein has focused on elucidating its mechanistic role in drug transport, interactions with various substrates, and physiological significance in different tissues. Additionally, understanding its 3D structure and transport mechanism can provide insights into designing better therapeutic agents and overcoming drug resistance. As such, SLC22A9 serves as a promising target for further studies aimed at improving drug delivery systems and enhancing treatment outcomes in conditions influenced by its transport capabilities.
